3rd Quarter - Report

STANTON PARK GROUP for BRAEBURN PHARMACEUTICALS, INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HCR - HR 1629 To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs; S. 250 Fairness in Orphan Drug Exclusivity Act; reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies

LobbyistCovered position, as disclosed
JAMES DERDERIAN —
VALERIE HENRY —
JOSEPH RACHINSKY —
ERIN STRAWN —
BRYAN WILLIAM WELLS Policy Advisor, Senator Pat Roberts

Contacted: HOUSE OF REPRESENTATIVES; Office of Natl Drug Control Policy (NDCP); SENATE

Bills named: H.R. 1629 (117th), S. 250 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.